144 related articles for article (PubMed ID: 19457675)
1. The structure-based design, synthesis, and biological evaluation of DNA-binding amide linked bisintercalating bisanthrapyrazole anticancer compounds.
Hasinoff BB; Zhang R; Wu X; Guziec LJ; Guziec FS; Marshall K; Yalowich JC
Bioorg Med Chem; 2009 Jul; 17(13):4575-82. PubMed ID: 19457675
[TBL] [Abstract][Full Text] [Related]
2. The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.
Hasinoff BB; Liang H; Wu X; Guziec LJ; Guziec FS; Marshall K; Yalowich JC
Bioorg Med Chem; 2008 Apr; 16(7):3959-68. PubMed ID: 18258442
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents.
Zhang R; Wu X; Yalowich JC; Hasinoff BB
Bioorg Med Chem; 2011 Dec; 19(23):7023-32. PubMed ID: 22041173
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, cytotoxicity, HuTopoIIα inhibitory activity and molecular docking studies of pyrazole derivatives as potential anticancer agents.
Alam R; Wahi D; Singh R; Sinha D; Tandon V; Grover A; Rahisuddin
Bioorg Chem; 2016 Dec; 69():77-90. PubMed ID: 27744115
[TBL] [Abstract][Full Text] [Related]
5. Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα.
Infante Lara L; Sledge A; Laradji A; Okoro CO; Osheroff N
Bioorg Med Chem Lett; 2017 Feb; 27(3):586-589. PubMed ID: 27998679
[TBL] [Abstract][Full Text] [Related]
6. Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase IIα.
Minniti E; Byl JAW; Riccardi L; Sissi C; Rosini M; De Vivo M; Minarini A; Osheroff N
Bioorg Med Chem Lett; 2017 Oct; 27(20):4687-4693. PubMed ID: 28919339
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Biological Evaluation of Pyrazolo[3,4-b]pyridin-4-ones as a New Class of Topoisomerase II Inhibitors.
Tabrizi MA; Baraldi PG; Baraldi S; Prencipe F; Preti D; Saponaro G; Romagnoli R; Gessi S; Merighi S; Stefanelli A; Fazzi D; Borea PA; Maia RC; Romeiro NC; Fraga CA; Barreiro EJ
Med Chem; 2015; 11(4):342-53. PubMed ID: 25494808
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
El-Adl K; El-Helby AA; Sakr H; Elwan A
Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human DNA topoisomerase IIα by two novel ellipticine derivatives.
Vann KR; Ergün Y; Zencir S; Oncuoglu S; Osheroff N; Topcu Z
Bioorg Med Chem Lett; 2016 Apr; 26(7):1809-12. PubMed ID: 26906637
[TBL] [Abstract][Full Text] [Related]
11. Discovery of mono- and disubstituted 1H-pyrazolo[3,4]pyrimidines and 9H-purines as catalytic inhibitors of human DNA topoisomerase IIα.
Pogorelčnik B; Brvar M; Žegura B; Filipič M; Solmajer T; Perdih A
ChemMedChem; 2015 Feb; 10(2):345-59. PubMed ID: 25522133
[TBL] [Abstract][Full Text] [Related]
12. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.
Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV
J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529
[TBL] [Abstract][Full Text] [Related]
13. A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone.
Liang H; Wu X; Guziec LJ; Guziec FS; Larson KK; Lang J; Yalowich JC; Hasinoff BB
J Chem Inf Model; 2006; 46(4):1827-35. PubMed ID: 16859314
[TBL] [Abstract][Full Text] [Related]
14. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
Liang H; Wu X; Yalowich JC; Hasinoff BB
Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllotoxin etoposide analogs.
Yadav AA; Chee GL; Wu X; Patel D; Yalowich JC; Hasinoff BB
Bioorg Med Chem; 2015 Jul; 23(13):3542-51. PubMed ID: 25922181
[TBL] [Abstract][Full Text] [Related]
16. The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα.
Yalowich JC; Wu X; Zhang R; Kanagasabai R; Hornbaker M; Hasinoff BB
Biochem Pharmacol; 2012 Jul; 84(1):52-8. PubMed ID: 22503743
[TBL] [Abstract][Full Text] [Related]
17. Design and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors.
Eissa IH; El-Naggar AM; El-Sattar NEAA; Youssef ASA
Anticancer Agents Med Chem; 2018; 18(2):195-209. PubMed ID: 28699490
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-β-benzyl ester derivatives as potent topoisomerase IIα inhibitors.
Han X; Zhong Y; Zhou G; Qi H; Li S; Ding Q; Liu Z; Song Y; Qiao X
Bioorg Med Chem; 2017 Jun; 25(12):3116-3126. PubMed ID: 28462840
[TBL] [Abstract][Full Text] [Related]
19. Biological evaluation of a halogenated triterpenoid, 2α-bromo-dihydrobelulonic acid as inhibitor of human topoisomerase IIα and HeLa cell proliferation.
Ghosh S; Mukhopadhyay S; Sarkar M; Mandal A; Das V; Kumar A; Giri B
Chem Biol Interact; 2017 Apr; 268():68-76. PubMed ID: 28254521
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics.
Lu Y; Yin W; Alam MS; Kadi AA; Jahng Y; Kwon Y; Rahman AFMM
Anticancer Agents Med Chem; 2020; 20(4):464-475. PubMed ID: 31763968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
